U.K. Pharmacovigilance Market is expected to expand at a CAGR of 11.9% from 2021 to 2028
U.K. Pharmacovigilance Industry Overview The U.K. pharmacovigilance market size is expected to reach USD 510.37 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 11.9% from 2021 to 2028. The increasing outsourcing and externalization of clinical trials by the majority of the pharmaceutical and biotechnological companies, regulatory mandates on clinical trial conduct, and post-marketing vigilance are likely to drive the market at an unprecedented rate throughout the forecast period. U.K. Pharmacovigilance Market Segmentation Grand View Research has segmented the U.K. pharmacovigilance market by service provider, product life cycle, type, process flow, therapeutic area, and end-use: Based on the Product Life Cycle Insights, the market is segmented into Pre-clinical, Phase I, Phase II, Phase III, Phase IV The post-marketing or phase IV clinical trial segment led the market with a share of over 75.0% in 20...